How does platinib work for lung cancer treatment?

Platinib (trade name: Pujihua®) blocks the signal transduction pathways of tumor cells by specifically inhibiting the kinase activity of fusion proteins or mutant proteins produced by RET gene mutations. RETGene mutation is an important driver of tumors such as non-small cell lung cancer (NSCLC). Platinib can directly act on this target and inhibit the proliferation and spread of tumor cells.

Platinib is mainly used to treat patients with the following lung cancers:

1.RETAdult patients with gene fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC): These patients usually have poor response to traditional chemotherapy drugs, and platinib can target their specific genetic mutations.

2.Patients with advanced or metastatic RETmutant medullary thyroid carcinoma (MTC) requiring systemic treatment Author: Although medullary thyroid cancer is different from NSCLC in pathological types, platinib can also exert a therapeutic effect by inhibiting RET mutations.

Multiple clinical trials have shown that platinib has good efficacy in the treatment of lung cancer patients with RET gene mutations. For example, in the ARROW study, the total number of RET fusion-positive NSCLC patients treated with platinib The overall response rate (ORR) reaches 57%-79%, and the median response time (mDOR) is longer.

Platinib is well tolerated and most patients tolerate its treatment. Common adverse reactions include fatigue, constipation, musculoskeletal pain, etc., but most are mild to moderate and can be effectively controlled with appropriate medical intervention and management.

Platinib, as an oral targeted therapy drug, has the advantages of easy use, significant efficacy, and good safety. In clinical application, doctors will develop individualized treatment plans based on the patient's specific situation and genetic testing results. For patients who meet the indications, platinib can be used as one of the first- or second-line treatment options.